Navigation Links
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
Date:7/7/2009

"would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

    Contact:
    At the Company:
    Howard J. Leonhardt, Chief Executive Officer
    (954) 835-1500


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
2. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
6. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
7. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
8. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
9. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  BioElectronics Corporation (OTC Pink: ... devices, comments on the FDA panel meeting for non-thermal ... Reclassification – Pulsed Shortwave Therapy Meeting was held on ... , USA.  The focus of the meeting was very ... to focus solely on the application of non-thermal shortwave ...
(Date:5/23/2013)... Conn. , May 23, 2013  CAS Medical Systems, ... medical devices for non-invasive patient monitoring, today announced that ... Officer,  will present at the 2 nd Annual Marcum ... Hyatt Hotel in New York City . ... p.m. ET in the Estate 10 room and will be ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... ) today announced the appointment of ... Officer.  Mr. Ramsay was most recently Vice President, ... http://photos.prnewswire.com/prnh/20100302/LA63139LOGO )     "With his established ... operational experience gained by working in our commercial ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2
... 14 The Clinical Trials,Bootcamp announces its inaugural ... staff and other participants in,clinical trial. It will ... Resort from May,14-17th, 2009. Physician investigators, clinical coordinators, ... how to incorporate,clinical trials into a practice, as ...
... in late 2008 or in early 2009 -, ... NUVO ) today announced positive results from the Phase ... rapidly produced and maintained anticoagulation with a rapid,return toward ... "NU172 has the potential to address many of ...
Cached Medicine Technology:Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 2Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 3Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172 4
(Date:5/24/2013)... 24, 2013 According to the National Institutes ... toxic epidermal necrolysis (TEN) that affects the skin and mucous ... adults under the age of 30 (i). In the ... and fever. As SJS advances, it affects the mucous ... and anus. Inflammation of the eye causes conjunctivitis (pink ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...
(Date:5/24/2013)... May 24, 2013 The producers of ... dates for Charlotte, North Carolina. It is one of the ... 500 companies. The city is populated with more than a ... cover residents in both North and South Carolina. Viewers who ... medically-related can tune into WAXN-TV 64 Eyewitness News during the ...
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... is happy to announce that it has donated $10,000 to ... the women held captive in Cleveland, Ohio. , “When the ... Jesus, Michelle Knight, and Amanda Berry and her daughter had ... a decade, we were shocked and horrified,” said Integrative Nutrition ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2
... April 23 (HealthDay News) -- It goes without saying that ... they can also be very expensive, an expert warns. ... a person bitten by a venomous snake, said Jill Heatley, ... in College Station. The total cost includes hospitalization, which ...
... The International and American Associations for Dental ... in children. These articles, titled "Hypoplasia-Associated Severe Early ... Page Caufield, New York University College of Dentistry) ... (lead author M.E.C. Elfrink, Academic Centre for Dentistry, ...
... destruction of the insulin-producing beta cells. Over 250,000 patients suffer ... daily insulin injections to maintain glucose metabolism. Replacement of the ... organ or isolated human beta cells is the only effective ... of organ donors this method can be offered to only ...
... St. Jude Children,s Research Hospital scientists have rewritten the ... it guards early brain cells from DNA damage. Such ... showed that cells in the developing brain require TopBP1 ... is copied prior to cell division. Investigators also reported ...
... That "brain freeze" headache you experience when eating ice cream ... change in brain blood flow, researchers report. What,s more, ... more troubling forms of headache such as migraine, the U.S. ... blood flow in 13 healthy adults as they sipped ice ...
... April 22 (HealthDay News) -- Tick season has started earlier ... gardeners and others who love the outdoors should take precautions ... People also should keep alert for symptoms of tick-borne ... tick-borne diseases such as Lyme disease, anaplasmosis and babesiosis -- ...
Cached Medicine News:Health News:Cost of Snakebite Therapy May Squeeze Victims' Wallets 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 2Health News:IADR/AADR publish studies on severe early childhood caries - proposes new classification 3Health News:Xenotransplantation as a therapy for type 1 diabetes 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 2Health News:Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor 3Health News:'Ice Cream Headaches' Might Offer Clues to Migraines 2Health News:Tick Season Starting Early This Year 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: